Evaluation of serum levels of calprotectin, lactoferrin and zinc in patients with type II diabetes mellitus.

Q4 Medicine

Wiadomosci lekarskie Pub Date : 2025-01-01 DOI:10.36740/WLek/201198

Hayder Neamah Hassan, Shaymaa Galeel Shamran, Majid A Z Albadry, Ali A Al Fahham

{"title":"Evaluation of serum levels of calprotectin, lactoferrin and zinc in patients with type II diabetes mellitus.","authors":"Hayder Neamah Hassan, Shaymaa Galeel Shamran, Majid A Z Albadry, Ali A Al Fahham","doi":"10.36740/WLek/201198","DOIUrl":null,"url":null,"abstract":"Objective: Aim: The current study aimed to evaluate the role of serum calprotectin, lactoferrin and serum zinc in patients with type II diabetes mellitus.Patients and methods: Materials and Methods: Sixty subjects have been investigated in this study, (40) patients with T2DM and 20 apparently healthy participants (control group) during the period between October 2021 to January 2022. Zinc was measured using a calorimetric method, while calprotectin and lactoferrin were measured by ELISA.Results: Results: The findings also revealed that levels of serum calprotectin and lactoferrin have significantly increased in in patients with T2DM as compared to healthy subjects. The result also showed that serum zin is decreased in patients groups. The correlation matrix exhibited that there was a strong positive correlation between calprotectin and lactoferrin, a significant negative correlation between zinc and calprotectin.Conclusion: Conclusions: It was concluded that high serum calprotectin and lactoferrin indicated a strong inflammatory status in T2DM patients. Zinc is likely to be negative affected by the high inflammatory response indicated by that high serum calprotectin.","PeriodicalId":23643,"journal":{"name":"Wiadomosci lekarskie","volume":"78 2","pages":"288-294"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiadomosci lekarskie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36740/WLek/201198","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Aim: The current study aimed to evaluate the role of serum calprotectin, lactoferrin and serum zinc in patients with type II diabetes mellitus.

Patients and methods: Materials and Methods: Sixty subjects have been investigated in this study, (40) patients with T2DM and 20 apparently healthy participants (control group) during the period between October 2021 to January 2022. Zinc was measured using a calorimetric method, while calprotectin and lactoferrin were measured by ELISA.

Results: Results: The findings also revealed that levels of serum calprotectin and lactoferrin have significantly increased in in patients with T2DM as compared to healthy subjects. The result also showed that serum zin is decreased in patients groups. The correlation matrix exhibited that there was a strong positive correlation between calprotectin and lactoferrin, a significant negative correlation between zinc and calprotectin.

Conclusion: Conclusions: It was concluded that high serum calprotectin and lactoferrin indicated a strong inflammatory status in T2DM patients. Zinc is likely to be negative affected by the high inflammatory response indicated by that high serum calprotectin.

查看原文本刊更多论文

2型糖尿病患者血清钙保护蛋白、乳铁蛋白和锌水平的评价。

目的：探讨血清钙保护蛋白、乳铁蛋白和血清锌在2型糖尿病患者中的作用。患者与方法：材料与方法：本研究在2021年10月至2022年1月期间调查了60名受试者，其中40名为T2DM患者，20名为表面健康的参与者（对照组）。用量热法测定锌含量，ELISA法测定钙保护蛋白和乳铁蛋白含量。结果：结果：研究结果还显示，与健康受试者相比，T2DM患者血清钙保护蛋白和乳铁蛋白水平显著升高。结果还显示，患者组血清锌含量明显降低。相关矩阵显示钙保护蛋白与乳铁蛋白呈显著正相关，锌与钙保护蛋白呈显著负相关。结论：结论：T2DM患者血清钙保护蛋白和乳铁蛋白水平高提示炎症状态强。高血清钙保护蛋白所显示的高炎症反应可能会对锌产生负面影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiadomosci lekarskie Medicine-Medicine (all)

CiteScore

0.80

自引率

0.00%

发文量

482